Literature DB >> 28912284

T1-Weighted Dynamic Contrast-Enhanced MR Perfusion Imaging Characterizes Tumor Response to Radiation Therapy in Chordoma.

P Santos1, K K Peck2,3, J Arevalo-Perez1, S Karimi1, E Lis1, Y Yamada4, A I Holodny1, J Lyo1.   

Abstract

BACKGROUND AND
PURPOSE: Chordomas notoriously demonstrate a paucity of changes following radiation therapy on conventional MR imaging. We hypothesized that dynamic contrast-enhanced MR perfusion imaging parameters of chordomas would change significantly following radiation therapy.
MATERIALS AND METHODS: Eleven patients with pathology-proved chordoma who completed dynamic contrast-enhanced MR perfusion imaging pre- and postradiation therapy were enrolled. Quantitative tumor measurements were obtained by 2 attending neuroradiologists. ROIs were used to calculate vascular permeability and plasma volume and generate dynamic contrast-enhancement curves. Quantitative analysis was performed to determine mean and maximum plasma volume and vascular permeability values, while semiquantitative analysis on averaged concentration curves was used to determine the area under the curve. A Mann-Whitney U test at a significance level of P < .05 was used to assess differences of the above parameters between pre- and postradiation therapy.
RESULTS: Plasma volume mean (pretreatment mean = 0.82; posttreatment mean = 0.42), plasma volume maximum (pretreatment mean = 3.56; posttreatment mean = 2.27), and vascular permeability mean (pretreatment mean = 0.046; posttreatment mean = 0.028) in the ROIs significantly decreased after radiation therapy (P < .05); this change thereby demonstrated the potential for assessing tumor response. Area under the curve values also demonstrated significant differences (P < .05).
CONCLUSIONS: Plasma volume and vascular permeability decreased after radiation therapy, suggesting that these dynamic contrast-enhanced MR perfusion parameters may be useful for monitoring chordoma growth and response to radiation therapy. Additionally, the characteristic dynamic MR signal intensity-time curve of chordoma may provide a radiographic means of distinguishing chordoma from other spinal lesions.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2017        PMID: 28912284      PMCID: PMC5759964          DOI: 10.3174/ajnr.A5383

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  Primary tumors of the sacrum: diagnostic imaging.

Authors:  J Llauger; J Palmer; S Amores; S Bagué; A Camins
Journal:  AJR Am J Roentgenol       Date:  2000-02       Impact factor: 3.959

Review 2.  Multiparametric MRI in prostate cancer management.

Authors:  Linda M Johnson; Baris Turkbey; William D Figg; Peter L Choyke
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

3.  Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.

Authors:  Kang-Wu Chen; Hui-Lin Yang; Jian Lu; Gen-Lin Wang; Yi-Ming Ji; Gui-Zhong Wu; Li-Fan Zhu; Jia-Yong Liu; Xiao-Qing Chen; Yong-Ping Gu
Journal:  J Neurooncol       Date:  2010-06-15       Impact factor: 4.130

Review 4.  Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS).

Authors:  Heon Joo Park; Robert J Griffin; Susanta Hui; Seymour H Levitt; Chang W Song
Journal:  Radiat Res       Date:  2012-01-09       Impact factor: 2.841

5.  Value of MRI in the diagnosis of non-clival, non-sacral chordoma.

Authors:  D Smolders; X Wang; A Drevelengas; F Vanhoenacker; A M De Schepper
Journal:  Skeletal Radiol       Date:  2003-04-26       Impact factor: 2.199

6.  Sacrococcygeal chordoma: MR imaging in 30 patients.

Authors:  Mi Sook Sung; Gyung Kyu Lee; Heung Sik Kang; Soon Tae Kwon; Jin Gyoon Park; Jin Suk Suh; Gil Ho Cho; Sung Moon Lee; Myung Hee Chung; Donald Resnick
Journal:  Skeletal Radiol       Date:  2004-10-08       Impact factor: 2.199

7.  Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions.

Authors:  S M Kumta; L Huang; Y Y Cheng; L T C Chow; K M Lee; M H Zheng
Journal:  Life Sci       Date:  2003-08-01       Impact factor: 5.037

Review 8.  Diagnostic imaging of solitary tumors of the spine: what to do and say.

Authors:  Mathieu H Rodallec; Antoine Feydy; Frédérique Larousserie; Philippe Anract; Raphaël Campagna; Antoine Babinet; Marc Zins; Jean-Luc Drapé
Journal:  Radiographics       Date:  2008 Jul-Aug       Impact factor: 5.333

Review 9.  Chordoma: the nonsarcoma primary bone tumor.

Authors:  Rashmi Chugh; Hussein Tawbi; David R Lucas; J Sybil Biermann; Scott M Schuetze; Laurence H Baker
Journal:  Oncologist       Date:  2007-11

10.  Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging: evaluation of tumor response to radiation therapy.

Authors:  Stacy Chu; Sasan Karimi; Kyung K Peck; Yoshiya Yamada; Eric Lis; John Lyo; Mark Bilsky; Andrei I Holodny
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-15       Impact factor: 3.468

View more
  7 in total

1.  Early response assessment after CyberKnife stereotactic radiosurgery for symptomatic vertebral hemangioma by quantitative parameters from dynamic contrast-enhanced MRI.

Authors:  Hongqing Zhuang; Ning Lang; Yongye Chen; Enlong Zhang; Qizheng Wang; Huishu Yuan
Journal:  Eur Spine J       Date:  2021-03-01       Impact factor: 3.134

2.  Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation.

Authors:  Yi-Hsiu Chung; Ching-Fang Yu; Shao-Chieh Chiu; Han Chiu; Shin-Ting Hsu; Ching-Rong Wu; Chung-Lin Yang; Ji-Hong Hong; Tzu-Chen Yen; Fang-Hsin Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-24       Impact factor: 9.236

3.  Chordoma: 18F-FDG PET/CT and MRI imaging features.

Authors:  Joshua T Olson; Doris E Wenger; Peter S Rose; Ivy A Petersen; Stephen M Broski
Journal:  Skeletal Radiol       Date:  2021-02-01       Impact factor: 2.199

4.  MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas.

Authors:  J Bai; J Shi; S Zhang; C Zhang; Y Zhai; S Wang; M Li; C Li; P Zhao; S Geng; S Gui; L Jing; Y Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-07       Impact factor: 3.825

5.  Differentiation of Skull Base Chondrosarcomas, Chordomas, and Metastases: Utility of DWI and Dynamic Contrast-Enhanced Perfusion MR Imaging.

Authors:  Y Ota; E Liao; A A Capizzano; A Baba; R Kurokawa; M Kurokawa; A Srinivasan
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-11       Impact factor: 4.966

6.  Current progress and future trends in imaging of musculoskeletal bone tumours.

Authors:  R Rajakulasingam; R Botchu
Journal:  J Clin Orthop Trauma       Date:  2021-10-07

7.  Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma.

Authors:  Ji Hyun Lee; Gyu Sang Yoo; Young Cheol Yoon; Hee Chul Park; Hyun Su Kim
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.